A D Michel1, L J Chambers, D S Walter. 1. Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Limited, Harlow, Essex, UK. anton.d.michel@gsk.com
Abstract
BACKGROUND AND PURPOSE: Antagonist effects at the P2X(7) receptor are complex with many behaving in a non-competitive manner. In this study, the effects of N-[2-({2-[(2-hydroxyethyl)amino]ethyl}amino)-5-quinolinyl]-2-tricyclo[3.3.1.1(3,7)]dec-1-ylacetamide (compound-17) and N (2)-(3,4-difluorophenyl)-N (1)-[2-methyl-5-(1-piperazinylmethyl)phenyl]glycinamide dihydrochloride (GW791343) on P2X(7) receptors were examined and their mechanism of action explored. EXPERIMENTAL APPROACH: Antagonist effects were studied by measuring agonist-stimulated ethidium accumulation in cells expressing human or rat recombinant P2X(7) receptors and in radioligand binding studies. KEY RESULTS: Compound-17 and GW791343 were non-competitive inhibitors of human P2X(7) receptors. Receptor protection studies using decavanadate and pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) showed that neither compound-17 nor GW791343 competitively interacted at the ATP binding site and so were probably negative allosteric modulators of the P2X(7) receptor. GW791343 prevented the slowly reversible blockade of the human P2X(7) receptor produced by compound-17 and inhibited [(3)H]-compound-17 binding to the P2X(7) receptor suggesting they may bind to similar or interacting sites. At rat P2X(7) receptors, compound-17 was a negative allosteric modulator but the predominant effect of GW791343 was to increase agonist responses. Antagonist interaction and radioligand binding studies revealed that GW791343 did not interact at the ATP binding site but did interact with the compound-17 binding site suggesting that GW791343 is a positive allosteric modulator of the rat P2X(7) receptor. CONCLUSIONS: Compound-17 was a negative allosteric modulator of human and rat P2X(7) receptors. GW791343 was a negative allosteric modulator of the human P2X(7) receptor but at the rat P2X(7) receptor its predominant effect was positive allosteric modulation. These compounds should provide valuable tools for mechanistic studies on P2X(7) receptors.
BACKGROUND AND PURPOSE: Antagonist effects at the P2X(7) receptor are complex with many behaving in a non-competitive manner. In this study, the effects of N-[2-({2-[(2-hydroxyethyl)amino]ethyl}amino)-5-quinolinyl]-2-tricyclo[3.3.1.1(3,7)]dec-1-ylacetamide (compound-17) and N (2)-(3,4-difluorophenyl)-N (1)-[2-methyl-5-(1-piperazinylmethyl)phenyl]glycinamide dihydrochloride (GW791343) on P2X(7) receptors were examined and their mechanism of action explored. EXPERIMENTAL APPROACH: Antagonist effects were studied by measuring agonist-stimulated ethidium accumulation in cells expressing human or rat recombinant P2X(7) receptors and in radioligand binding studies. KEY RESULTS: Compound-17 and GW791343 were non-competitive inhibitors of human P2X(7) receptors. Receptor protection studies using decavanadate and pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) showed that neither compound-17 nor GW791343 competitively interacted at the ATP binding site and so were probably negative allosteric modulators of the P2X(7) receptor. GW791343 prevented the slowly reversible blockade of the humanP2X(7) receptor produced by compound-17 and inhibited [(3)H]-compound-17 binding to the P2X(7) receptor suggesting they may bind to similar or interacting sites. At rat P2X(7) receptors, compound-17 was a negative allosteric modulator but the predominant effect of GW791343 was to increase agonist responses. Antagonist interaction and radioligand binding studies revealed that GW791343 did not interact at the ATP binding site but did interact with the compound-17 binding site suggesting that GW791343 is a positive allosteric modulator of the ratP2X(7) receptor. CONCLUSIONS: Compound-17 was a negative allosteric modulator of human and rat P2X(7) receptors. GW791343 was a negative allosteric modulator of the humanP2X(7) receptor but at the ratP2X(7) receptor its predominant effect was positive allosteric modulation. These compounds should provide valuable tools for mechanistic studies on P2X(7) receptors.
Authors: Prisca Honore; Diana Donnelly-Roberts; Marian T Namovic; Gin Hsieh; Chang Z Zhu; Joe P Mikusa; Gricelda Hernandez; Chengmin Zhong; Donna M Gauvin; Prasant Chandran; Richard Harris; Arturo Perez Medrano; William Carroll; Kennan Marsh; James P Sullivan; Connie R Faltynek; Michael F Jarvis Journal: J Pharmacol Exp Ther Date: 2006-09-18 Impact factor: 4.030
Authors: Anton D Michel; Mengle Xing; Kyla M Thompson; Clare A Jones; Patrick P A Humphrey Journal: Eur J Pharmacol Date: 2006-02-17 Impact factor: 4.432
Authors: L Stokes; L-H Jiang; L Alcaraz; J Bent; K Bowers; M Fagura; M Furber; M Mortimore; M Lawson; J Theaker; C Laurent; M Braddock; A Surprenant Journal: Br J Pharmacol Date: 2006-10-09 Impact factor: 8.739
Authors: D Ferrari; C Pizzirani; S Gulinelli; G Callegari; P Chiozzi; M Idzko; E Panther; F Di Virgilio Journal: Br J Pharmacol Date: 2007-01-08 Impact factor: 8.739
Authors: Jingsheng Xia; Jason C Lim; Wennan Lu; Jonathan M Beckel; Edward J Macarak; Alan M Laties; Claire H Mitchell Journal: J Physiol Date: 2012-03-12 Impact factor: 5.182
Authors: A D Michel; W C Clay; S W Ng; S Roman; K Thompson; J P Condreay; M Hall; J Holbrook; D Livermore; S Senger Journal: Br J Pharmacol Date: 2008-07-28 Impact factor: 8.739
Authors: S Roman; F S Cusdin; E Fonfria; J A Goodwin; J Reeves; S C Lappin; L Chambers; D S Walter; W C Clay; A D Michel Journal: Br J Pharmacol Date: 2009-10-08 Impact factor: 8.739